Diarrhea Clinical Trial
Official title:
Phase II, Double-blind, Randomized, Two-stage, Placebo-controlled Proof of Concept Study in Colorectal Cancer Patients Receiving 5-FU Based Chemotherapy to Assess the Efficacy of Elsiglutide (ZP1846)Administered s.c. in the Prevention of Chemotherapy Induced Diarrhea(CID)
The main objective of this study will be to obtain data on the efficacy of elsiglutide in preventing Chemotherapy Induced Diarrhea (CID) in patients with colorectal cancer receiving 5-FU based chemotherapy (FOLFOX4 or FOLFIRI regimen) in comparison to placebo.
Status | Completed |
Enrollment | 138 |
Est. completion date | October 2013 |
Est. primary completion date | January 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Written informed consent; 2. Male or female patient = 18 years of age; 3. Confirmed diagnosis of colorectal cancer; 4. Chemotherapy naïve patient; 5. Patient scheduled to receive a FOLFOX4 or FOLFIRI chemotherapy regimen according to the following scheme and dosage (1st cycle): AGENT DOSE ROUTE/DURATION DAYS Oxaliplatin or Irinotecan 85/180 mg m2 i.v. infusion/2h 1 FolinicAcid (leucovorin) 200 mg m2 i.v. infusion/2h 1+2 5-Fluorouracil (5FU) 400 mg m2 i.v. bolus 1+2 5-Fluorouracil (5FU) 600 mg m2 i.v. infusion/22h 1+2 6. A performance status of = 2 according to the Eastern Cooperative Oncology Group(ECOG); 7. Non-fertile patient or fertile patient (male or female) using reliable contraceptive measures 8. Female patient of childbearing potential; need to have a negative pregnancy test at screening. Inclusion criteria 1-8 will be verified at screening. Inclusion criteria 8 will be re-confirmed on Day 1. Exclusion Criteria: 1. Inability to understand study procedures and/or cooperate with the study Investigator; 2. Any investigational drugs within 30 days before enrollment in the study or foreseen use of investigational agents during the study; 3. Patient with any type of ostomy; 4. Any previous radiotherapy to the abdomen or pelvis; 5. Scheduled to receive radiotherapy to abdomen or pelvis during the study (Day 1 to Day 14); 6. Scheduled to receive any concomitant chemotherapeutic agent other than FOLFOX4 or FOLFIRI agents (Oxaliplatin, Irinotecan, Folinic acid, 5-FU) from Day 1 to Day 14; 7. Previous use or scheduled to receive monoclonal antibodies (e.g. bevacizumab, cetuximab, etc) during the study (From Day 1 to Day 14); 8. Major surgery within the previous 3 weeks; 9. Any type of condition leading to chronic diarrhea, including but not limited to inflammatory bowel diseases (e.g. ulcerative colitis and Crohn's disease), chronic diarrhea of presumed or confirmed infectious origin and irritable bowel syndrome; 10. Any diarrhea in the 48 hours preceding study drug administration; 11. Use of anti-diarrheal agents within the 48 hours prior to study drug administration; 12. Use of laxatives within 7 days prior to study drug administration; 13. Use of antibiotics within 7 days prior to study drug administration; 14. History of chronic (= 30 consecutive days) use of laxatives; 15. Active and ongoing systemic infection; 16. Lactating woman; 17. History of hypersensitivity or allergies to drugs or compounds potentially related to this investigational drug class; 18. Previous exposure to GLP-2 or other compounds in this investigational drug class; 19. Abnormal laboratory values, including - Aspartate aminotransferase (AST) = 5 x upper limit of normal - Alanine aminotransferase (ALT) = 5 x upper limit of normal - Bilirubin > 2 mg/dL (34 µmol/L) - Creatinine > 2 mg/dL (177 µmol/L) - Albumine < 2 g/dL (20 g/L) - Neutrophils< 1.5 x109/L - Platelet count < 100 x109/L; 20. Concomitant bleeding disorders; 21. Other serious concomitant illness, which could interfere with the study; 22. Patient who participated in a previous study with elsiglutide (ZP1846). Exclusion criteria 1-9 and 12-22 will be verified at screening. Exclusion criteria 10 and 11 will be checked on Day 1 only. Exclusion criteria 12, 13 and 15 will be re-checked on Day 1. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Bulgaria | Department of Chemotherapy, Complex Oncology Center | Ruse | |
Bulgaria | Chemotherapy Department, Complex Oncology Center | Shumen | |
Bulgaria | Department of Chemotherapy Specialized Hospital for Active Treatment of Oncological Diseases | Sofia | |
Bulgaria | Department of Chemotherapy Specialized Hospital for Active Treatment of Oncological Diseases | Sofia | |
Bulgaria | Oncology Clinic, Multiprofile Hospital for Active Treatment "Sveta Marina" | Varna | |
Hungary | Semmelweis University, Department of Diagnostic Radiology and Oncotherapy | Budapest | |
Hungary | Kenezy Hospital, Department of Clinical Pharmacology, Infectology and Allergology | Debrecen | |
Hungary | Petz Aladar County Teaching Hospital, Center of Oncologic Radiology Hungary | Gyor | |
Hungary | Szeged Medical University Department of Oncology and Oncotherapy | Szeged | |
Romania | Dr. Constantin Opris Clinical Country Emergency Hospital Baia Mare, Department of Oncology | Baia Mare | Maramures County |
Romania | Fundeni Clinical Institute - Medical Oncology Department | Bucharest | |
Romania | Prof. Dr. Ion Chiricuta Institute of Oncology, Medical Oncology Department | Cluj-Napoca | Cluj County |
Romania | Euroclinic Oncology Center SRL - Medical Oncology Department | Iasi | Iasi county |
Romania | Sf. Ioan cel Nou Emergency Clincal County Hospital | Suceava | Suceava county |
Russian Federation | Regional Oncology Center | Arkhangelsk | |
Russian Federation | Kursk Regional Clinical Oncology Center | Kursk | |
Russian Federation | Pyatigorsk Oncology Center | Pyatigorsk | |
Russian Federation | City #9 Hospital | Saint-Petersburg | St. Petersburg |
Russian Federation | City Clinical Oncology Center | Saint-Petersburg | St. Petersburg |
Russian Federation | Regional Clinical Oncology Center - Chemotherapy Department | Ulyanovsk | Ulyanovsk region |
Russian Federation | Regional Oncology Hospital | Yaroslavl |
Lead Sponsor | Collaborator |
---|---|
Helsinn Healthcare SA |
Bulgaria, Hungary, Romania, Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Patients experiencing Diarrhea | Severity of Diarrhea will be classified according to the NCI-CTCAE. | Day 1 to Day 14 | No |
Secondary | Safety and tolerability of the administered repeated doses of elsiglutide (ZP1846) will be evaluated | Safety will be evaluated by monitoring: Physical examination Vital signs Clinical laboratory parameters (hematology, blood chemistry, urinalysis) 12-lead ECG AEs Immunogenicity testing in a subset of patients |
Day 1 to Day 32 | Yes |
Secondary | PK of elsiglutide will be evaluated | The followin standard PK parameters will be evaluated: Tmax, Cmax, AUC0-t, AUC0-24, AUC0-8, t1/2Z, ?Z, CL/F, VZ/F, the effect of multiple dosing will be evaluated (accumulation ratio). Blood sampling for PK will be performed at: pre-dose, 2h, 4, 6, 12, 24 h post-dose |
Day 1 to Day 5 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06283784 -
Study To Evaluate The Efficacy of a Proprietary Mix of Live Probiotics In The Prophylaxis Of Diarrhea In Adult Patients
|
N/A | |
Recruiting |
NCT03851835 -
Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis
|
Phase 3 | |
Completed |
NCT04003181 -
The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon
|
N/A | |
Completed |
NCT03596827 -
The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection
|
N/A | |
Recruiting |
NCT05372068 -
Cement flooRs AnD chiLd hEalth (CRADLE)
|
N/A | |
Completed |
NCT03972618 -
Evaluation of the Efficacy of Sawyer Point One Filters in Schools and Homes in the Dominican Republic
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT05052489 -
Registry and Clinical Observation of Children With Diarrhoeal Disease
|
||
Completed |
NCT02428647 -
Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation
|
N/A | |
Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT01739231 -
Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults
|
Phase 1/Phase 2 | |
Completed |
NCT01968408 -
Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children
|
Phase 3 | |
Not yet recruiting |
NCT01382199 -
Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
|
Phase 3 | |
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT01438645 -
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
|
N/A | |
Terminated |
NCT01472211 -
Water-based Zinc Intervention Trial in Zinc Deficient Children
|
Phase 0 | |
Terminated |
NCT01048567 -
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
|
Phase 2 | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT00760851 -
Yogurt Study in Children 2-4 Years Old Attending Daycare
|
Phase 3 |